A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects. - Wikidata - wikimedia - TriplyDB

A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects.

A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects.

http://www.wikidata.org/entity/Q34177254

about

The GRIP1:IRF3 interaction as a target for glucocorticoid receptor-mediated immunosuppression Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects Doubling the Size of the Glucocorticoid Receptor Ligand Binding Pocket by Deacylcortivazol Identification of glucocorticoid receptor domains involved in transrepression of transforming growth factor-beta action Ligand structural motifs can decouple glucocorticoid receptor transcriptional activation from target promoter occupancy Therapeutic and adverse effects of a non-steroidal glucocorticoid receptor ligand in a mouse model of multiple sclerosis.Crosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatases Antiinflammatory properties of a plant-derived nonsteroidal, dissociated glucocorticoid receptor modulator in experimental autoimmune encephalomyelitis.Minireview: latest perspectives on antiinflammatory actions of glucocorticoids.Abrogation of glucocorticoid receptor dimerization correlates with dissociated glucocorticoid behavior of compound a.Ginsenoside Rh1 potentiates dexamethasone's anti-inflammatory effects for chronic inflammatory disease by reversing dexamethasone-induced resistance.Identification of pathway-selective estrogen receptor ligands that inhibit NF-kappaB transcriptional activity.A fully dissociated compound of plant origin for inflammatory gene repression Noncanonical mechanisms to regulate nuclear receptor signaling.Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile.11beta-hydroxysteroid dehydrogenase type 1 as a novel therapeutic target in metabolic and neurodegenerative disease.The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis.New and improved glucocorticoid receptor ligands.Conformational changes of the glucocorticoid receptor ligand binding domain induced by ligand and cofactor binding, and the location of cofactor binding sites determined by hydrogen/deuterium exchange mass spectrometry Insight into the molecular mechanisms of glucocorticoid receptor action promotes identification of novel ligands with an improved therapeutic index.Understanding stress through the genome.Modelling the glucocorticoid receptor and producing therapeutic agents with anti-inflammatory effects but reduced side-effects.Regulation of human bone marrow stromal cell proliferation and differentiation capacity by glucocorticoid receptor and AP-1 crosstalk.The Development of Novel Therapies for Rheumatoid Arthritis Differential targeting of brain stress circuits with a selective glucocorticoid receptor modulator.The Genomic Context and Corecruitment of SP1 Affect ERRα Coactivation by PGC-1α in Muscle Cells.Selective amplification of glucocorticoid anti-inflammatory activity through synergistic multi-target action of a combination drug Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases.Minireview: live and let die: molecular effects of glucocorticoids on bone cells.Anti-inflammatory glucocorticoid drugs: reflections after 60 years.Non-genomic effect of glucocorticoids on cardiovascular system.The multiple facets of glucocorticoid action in rheumatoid arthritis.Design of small molecules targeting transcriptional activation by NF-κB: overview of recent advances.Newer glucocorticosteroids and corticosteroid resistance reversal in asthma.Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events.Generating diversity in glucocorticoid receptor signaling: mechanisms, receptor isoforms, and post-translational modifications.Corticosteroid receptor signalling modes and stress adaptation in the brain.Novel glucocorticoid receptor agonists in the treatment of asthma.Compound A influences gene regulation of the Dexamethasone-activated glucocorticoid receptor by alternative cofactor recruitment.Understanding how long-acting β2 -adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids in asthma - an update.

P2860

Q24299196-9C78733A-EE27-4C10-B586-F0C7378CD9BE Q24630458-1DECFDE4-97CD-4BE7-8164-B0D073DBDB7D Q27649439-2F1DBCAD-B68D-4BF6-BFCB-091A272AC702 Q28155857-07BE5649-5B30-4EA1-BD30-F9A16038ADC7 Q28568722-3C0C4E9E-5458-4194-A5FD-65FACD9C3889 Q33517628-7343A49C-EB00-4B87-917B-AA31C5197896 Q33636430-9A4CF6DC-B720-41E7-8190-A78D82EE640B Q33670387-D0D1C4A5-3F20-47DD-A21D-FDFDACD9E6A1 Q33670499-3576851F-780A-439F-BD77-08D1631E061C Q33707026-7A12BAD3-D19E-4A1B-B72D-45A0DBA2C408 Q33767092-4285EC68-198A-4477-9F84-D04376B98648 Q33849756-88543E13-988B-4334-8783-244CB362FF24 Q34115914-EEA1AE85-77AF-4F07-A39B-6D77BC901A30 Q34338685-37F7BDE9-798F-4A83-9504-9C16116E1837 Q34717142-5DCBF587-BDAE-4AB1-9994-B136E1BB876A Q35593949-52112D61-446E-4C07-8020-25AB75DF5FD1 Q36132386-85B4CBD4-27B7-475A-BAAE-9DF0B936ADD7 Q36322079-AC0FF370-ED55-4B57-8F13-CDA85F1820B8 Q36458264-BE775DBB-4142-48AC-B2BD-E3824038379A Q36536770-78AC0031-9326-4858-8128-0A57F32B9150 Q36559964-5631BE6D-F7DE-4DFA-ADC7-5B106C6C9B33 Q36670211-078B4066-0991-4488-BDB9-7FD204D12720 Q36714018-6C2A77DB-1CB0-4138-93AC-7D97BC2D5DFB Q36801049-D72109AC-E6F1-44D5-BFFE-F84A4B5C492C Q36835455-EFC06463-1EFA-4288-81E4-B338EB8E437F Q37146493-4E5DE11A-EF64-4CF6-8B15-E7ECF8A0D227 Q37207076-D680E374-DA1B-4309-9296-C4DC96E23467 Q37447509-F4C44FED-B64E-4588-8360-019B9C597A31 Q37499649-41CC82CF-AA3E-46FB-857A-D82C0F4EF683 Q37808969-65A5794C-AFD0-4902-B6C6-626EB39BB889 Q38045751-FD4A135A-04EE-47AC-AE77-B9F81D11A222 Q38050401-6CC30EEC-A0FB-4346-8EAF-C7A1C3A1B47F Q38089908-041A7864-E6C6-49CC-955D-F7754260FDD9 Q38162976-C628F1B6-BD01-47F8-908F-8BBF4EC1EDD7 Q38247488-AF035C2B-7E03-4674-AE5D-B53416F5404D Q38471444-C0A5B69C-440C-47A6-81E6-D157F08B4141 Q38471565-3DF97E66-6747-4ED0-B7E6-16E0C4B7B098 Q38570469-C9E5269A-E0D6-4370-8A9C-88DD6BF280A6 Q38642503-46CFDAFB-E56E-4D77-9264-1A30BBED50EC Q38959067-2871E7B2-359F-4487-8C31-B37B4FF50566

P2860

A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects.

http://www.wikidata.org/entity/Q34177254

description

2003 nî lūn-bûn

@nan

2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects.

@ast

A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects.

@en

A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects.

@nl

type

label

A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects.

@ast

A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects.

@en

A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects.

@nl

prefLabel

A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects.

@ast

A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects.

@en

A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects.

@nl

P1433

Q34177254-7D4AE360-7C9A-470C-B9FE-884AA9FBA30B

P1476

Q34177254-BE51C40D-CD65-4A4B-8059-16DB6E3B08DE

P2093

Q34177254-1344185B-D22C-4F7B-AB07-D3F54B5C7590

Q34177254-1B76FEA3-B149-4D40-A65F-C6225F6B1FFC

Q34177254-4EDE3CB7-6414-46F0-A351-DB90ECC16C06

Q34177254-50BC050F-E889-405F-AB71-944EBA63FEE2

Q34177254-6BFBE388-8DE0-47A2-A2EB-0B1D3976E8B5

Q34177254-721FB714-529D-48F5-B4A7-A7D2350546DB

Q34177254-79691BEE-5270-4570-860C-8AFD95C09E30

Q34177254-7BAC104A-F6FE-47A4-BBF3-5888DEF951FB

Q34177254-819E0ABE-C42B-4B28-B181-A2452CC3C509

Q34177254-94575CE4-FC64-48CC-BB76-962122073E0B

P304

Q34177254-355B2AD5-930F-486E-B98F-F42AB56E5F2F

P31

Q34177254-5E45AF4A-6367-4899-A7CC-029E8AFB563C

P356

Q34177254-21991CA3-8521-455D-BBB1-583250F75799

P433

Q34177254-532FF52A-92CF-4013-BBDD-1C711DFE61D6

P478

Q34177254-3342721F-BA0C-4664-AB3A-B3E9C211C28E

P577

Q34177254-087FD642-6459-4371-A7F5-14AD842C46FA

P5875

Q34177254-61EDC7DA-C0F0-4903-ABC9-2E8AC26F6965

P698

Q34177254-EC36C6D7-AFDD-4CEB-9C9F-63C7B537E0E9

P356

P1433

Molecular Endocrinology

P1476

A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects.

@en

P2093

Ben Lane

http://www.w3.org/2001/XMLSchema#string

Chun Wei Lin

http://www.w3.org/2001/XMLSchema#string

Curtis M Tyree

http://www.w3.org/2001/XMLSchema#string

George W Carter

http://www.w3.org/2001/XMLSchema#string

Jay R Luly

http://www.w3.org/2001/XMLSchema#string

Jeffrey N Miner

http://www.w3.org/2001/XMLSchema#string

Jon Rosen

http://www.w3.org/2001/XMLSchema#string

Junlian Hu

http://www.w3.org/2001/XMLSchema#string

Marc Elgort

http://www.w3.org/2001/XMLSchema#string

Masaki Nakane

http://www.w3.org/2001/XMLSchema#string

P304

860-869

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1210/ME.2002-0355

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2003-02-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10899937

http://www.w3.org/2001/XMLSchema#string

P698

12586843

http://www.w3.org/2001/XMLSchema#string